Abstract
摘要
相似文献
1
Spotlight on interleukin-2 (IL-2, proleukin).
Proj Inf Perspect. 2001 Mar(32):13-5.
2
Interleukin-2 (IL-2, Proleukin) and immune function.
Proj Inf Perspect. 2003 Jan(35):16.
3
IL-2 immunotherapy does not benefit patients taking antiretrovirals.
AIDS Patient Care STDS. 2009 Mar;23(3):221-2.
4
Aldesleukin shows promise.
AIDS Patient Care STDS. 1999 May;13(5):307.
5
Aldesleukin therapy in HIV-infected patients.
Am J Health Syst Pharm. 1998 Jul 15;55(14):1520-3. doi: 10.1093/ajhp/55.14.1520.
6
Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2.
Clin Infect Dis. 2003 Oct 15;37(8):e115-20. doi: 10.1086/378293. Epub 2003 Sep 24.
7
[Use of interleukin-2 (proleukin, aldesleukin) in oncological practice].
Vopr Onkol. 2003;49(6):776-82.
8
Interleukin-2 in HIV infection.
Am J Health Syst Pharm. 1995 Jun 15;52(12):1345-6. doi: 10.1093/ajhp/52.12.1345.
9
A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).
J Infect Dis. 2006 Dec 15;194(12):1672-6. doi: 10.1086/509508. Epub 2006 Nov 8.
10
Phase III trial of IL-2.
AIDS Patient Care STDS. 1999 Dec;13(12):753-4.
Zotero 插件